OTC Impact: DoD Nexium Formulary Move Could Preface Future Cost-Cutting
This article was originally published in The Tan Sheet
Executive Summary
The Defense Department's decision to cease pharmacy benefit coverage of AstraZeneca's Nexium could pave the way for similar cost-cutting measures in other federal employee health plans